OPEN ACCESS Freely available online

Epigenetics Research: Open Access

Perspective

Histone Modifications in Breast Cancer Stem Cells: Implications for Therapeutic Resistance

Ryan Grindley*

Department of Biomedical Sciences, University of Alberta, Edmonton, Canada

DESCRIPTION

Emerging evidence suggests that histone modifications play crucial roles in maintaining Breast Cancer Stem Cell (BCSC) populations, contributing to treatment resistance and tumor recurrence. Breast cancer stem cells represent a small but critical population of tumor cells that drive cancer progression, metastasis, and therapeutic resistance. Recent epigenetic studies have revealed that histone modifications, particularly H3K27me3 and H3K4me3, play essential roles in maintaining BCSC identity and function.

The Polycomb Repressive Complex 2 (PRC2), which catalyzes H3K27 trimethylation, is frequently overexpressed in breast cancer and correlates with poor clinical outcomes. PRC2-mediated silencing of differentiation genes maintains BCSCs in a pluripotent state, preventing their differentiation into less tumorigenic cell types. Pharmacological inhibition of EZH2, the catalytic subunit of PRC2, has shown promise in preclinical models, leading to BCSC differentiation and increased sensitivity to conventional therapies.

Conversely, H3K4me3 marks, deposited by the MLL1 complex, are enriched at the promoters of stem cell maintenance genes such as *SOX2*, *NANOG*, and *OCT4* in BCSCs. The interaction between *MLL1* and transcription factors like *STAT3* creates a positive feedback loop that sustains stem cell gene expression. Targeting this pathway with MLL1 inhibitors has demonstrated efficacy in reducing BCSC populations in triple-negative breast cancer models. The dynamic interplay between activating and repressive histone marks creates a unique chromatin landscape in BCSCs. Bivalent domains, characterized by the co-occurrence of H3K4me3 and H3K27me3, are particularly abundant in these cells. These domains poise genes for rapid activation in response to environmental cues, contributing to the phenotypic plasticity that enables BCSCs to adapt to therapeutic stress.

Metabolic reprogramming in BCSCs is also regulated by histone modifications. The expression of glycolytic enzymes and metabolic regulators is controlled by H3K27 acetylation, which is maintained by the histone acetyltransferase p300. Targeting p300 with specific inhibitors disrupts BCSC metabolism and reduces their survival under nutrient-limited conditions. The role of histone demethylases in BCSC biology is equally important. *LSD1*, which demethylates H3K4me1/2, is highly expressed in BCSCs and required for their self-renewal capacity. *LSD1* inhibitors have shown promising results in clinical trials, particularly when combined with differentiation-inducing agents. Recent studies have also highlighted the importance of histone variant H3.3 in BCSC maintenance. The incorporation of histone variant into chromatin at active regulatory elements facilitates rapid gene expression changes in response to therapeutic pressure. Understanding these mechanisms provides new avenues for therapeutic intervention.

CONCLUSION

The clinical implications of these findings are significant. Combination therapies targeting both histone-modifying enzymes and conventional cancer pathways may be more effective than single-agent treatments. Current clinical trials are evaluating the safety and efficacy of epigenetic drugs in combination with chemotherapy, targeted therapy, and immunotherapy. Future research should focus on understanding the temporal dynamics of epigenetic changes in the GBM microenvironment and developing strategies to prevent or reverse these modifications. The identification of epigenetic biomarkers that predict treatment response will be essential for personalized therapy approaches. Single-cell epigenetic analysis technologies are providing new insights into the heterogeneity of epigenetic regulation within the GBM microenvironment, paving the way for more targeted therapeutic interventions.

Correspondence to: Ryan Grindley, Department of Biomedical Sciences, University of Alberta, Edmonton, Canada, E-mail: ryan@grindley.edu

Received: 03-Mar-2025, Manuscript No. EROA-25-38327; **Editor assigned:** 05-Mar-2025, PreQC No. EROA-25-38327 (PQ); **Reviewed:** 19-Mar-2025, QC No. EROA-25-38327; **Revised:** 26-Mar-2025, Manuscript No. EROA-25-38327 (R); **Published:** 02-Apr-2025, DOI: 10.35248/EROA.25.7.203

Citation: Grindley R (2025). Histone Modifications in Breast Cancer Stem Cells: Implications for Therapeutic Resistance. J Epigenetics Res. 7:203.